Current Research Studies

A Long-term Observational Study Evaluating Sarepta Therapeutics, Inc's Exon-Skipping Therapies in Patients with Duchenne Muscular Dystrophy under Conditions of Routine Clinical Practice

Sarepta Registry 4658-403

What is the goal of the study?

An observational study that is designed to collect available data on DMD patients receiving an FDA approved exon skipping drug in routine clinical practice. Data will be collected from the medical record after routine visits for at least 5 years.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: